• VIDEO: Avicenna Alliance
    at the European Parliament

    At the invitation of the European Parliament, Avicenna Alliance's leaders supported by senior people from FDA, ANSYS, Medtronic, CIPLA, VPHi, EFGCP and RPP, have explained to delegations from Europe, USA, India and Japan the central role played by in silico healthcare to accelerate medical innovation.

    View the video!

Avicenna Alliance news

Dassault to enhance clinical tech with Medidata acquisition

Dassault Systèmes acquired Medidata, major player in information technologies for clinical trials, for $5.5 billion. This represents to...

find out more ›

Promote adoption of In Silico Trials through EMA’s strategy on Regulatory Science to 2025

The European Medicine Agency (EMA) has recently published a document that describes its strategy until 2025....

find out more ›

European Strategy for High Performance Computing

On the 17 June, the European Commission published a presentation explaining why they indicated High Performance Computing (HPC) as a priority area for...

find out more ›

Show all activites

Avicenna Alliance the Association for Predictive Medicine

The Avicenna Alliance, is an association of industry and renowned academia/healthcare organizations who have a commercial or research interest in the development of in silico medicine. The Association, established in 2015, has its origins in the Virtual Physiological Human Initiative, a European Commission endorsed research area on computer modeling and simulation. Tasked by the European Commission with developing a “Roadmap for in silico medicine”, the Association now seeks to put this roadmap into policy and ensure the development of a regulated in silico market.

This Association bridges the gap between the scientific community, industry and policy makers by advocating for policy changes that take into account scientific and market developments.

read more

Avicenna Alliance: 
enhanced knowledge, improved decisions, better outcomes